Clinical trial · Interventional
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
Prevention of Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer
NCT01281787CI-TRIAL-00014870PRESAGEcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to assess whether prophylactic treatment with metoprolol or losartan is able to reduce the incidence of atrial fibrillation (AF) in patients undergoing thoracic surgery for lung cancer, showing elevated plasma levels in NT probrain natriuretic peptide (NT-proBNP), measured in the perioperative period.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atrial Fibrillation | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Losartan | Drug | — | UNRESOLVED |
| Metoprolol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Losartan
- description
- angiotensin II-receptor blocker
- interventionNames
- Drug: Losartan
- type
- NO_INTERVENTION
- label
- no treatment
- description
- no preventive treatment
- type
- ACTIVE_COMPARATOR
- label
- Metoprolol
- description
- beta-adrenergic antagonist
- interventionNames
- Drug: Metoprolol
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients of both sexes with age ≥ 18 years * Thoracic surgery for lung cancer * Evidence of elevated perioperative NT-proBNP * Written informed consent Exclusion Criteria: * Hypersensitivity and / or intolerance to metoprolol or losartan * History of heart failure * Left ventricular ejection fraction \<50% measured by echocardiographic techniques (Simpson rule) * Permanent atrial fibrillation * Antiarrhythmic therapy * Current therapy with beta-blockers, angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors * Systolic blood pressure \<95 mmHg * Pregnant and lactating women Additional exclusion criteria for therapy with beta-blocker: * History of sick sinus syndrome, evidence of AV-block grade II or greater * Heart rate \<65 b / m * History of bronchial asthma, severe bronchopneumopathy, evidence of bronchospasm
References
Publications (0)
Data not yet available
No reference posted for this study.